Results 181 to 190 of about 157,713 (224)

Deciphering the transcriptomic landscape of systemic lupus erythematosus-associated pulmonary arterial hypertension. [PDF]

Respir Res
Li Y, Qian J, Deng X, Ma L, Yuan Q, Wang Q, Tian Z, Zeng X, Yang X, Zhao J, Li M.   +10 more
europepmc   +1 more source

Immune cell dynamics in heart failure: implicated mechanisms and therapeutic targets

ESC Heart Failure, EarlyView.
Abstract The relationship between heart failure (HF) and immune activation has garnered significant interest. Studies highlight the critical role of inflammation in HF, affecting cardiac structure and function. Despite promising anti‐inflammatory therapies, clinical trials have faced challenges, indicating an incomplete understanding of immune ...
Gen Li, Wu He, Dao Wen Wang
wiley   +1 more source

The Importance of Dose Escalation in the Treatment of Pulmonary Arterial Hypertension with Treprostinil. [PDF]

Biomedicines
Kędzierski P, Banaszkiewicz M, Florczyk M, Piłka M, Mańczak R, Wieteska-Miłek M, Szwed P, Kasperowicz K, Wrona K, Darocha S, Torbicki A, Kurzyna M.   +11 more
europepmc   +1 more source

1123-188 Role of amiodipine in preventing and reversing monocrotaline-induced pulmonary arterial hypertension in rats

, 2004
Eiichiro Mawatari, Minoru Hongo, Akio Sakai, Ruan Zonghai, Fumiaki Ogiwara, Noboru Watanabe, Yuichi Kamiyoshi, Osamu Kinoshita, Keishi Kubo   +8 more
openalex   +1 more source

Localization, Proteolytic Processing, and Binding Partners of Versican Isoforms in Vascular Lesions of Pulmonary Arterial Hypertension. [PDF]

J Histochem Cytochem
Westöö C, Mutgan AC, van der Have O, Mead TJ, Ahmed S, Lampei E, Koch CD, Norvik C, Aspberg A, Bech M, Peruzzi N, Brunnström H, Kwapiszewska G, Rådegran G, Apte SS, Tran-Lundmark K.   +15 more
europepmc   +1 more source

Predictors of sustained reverse remodelling in patients with heart failure with reduced ejection fraction

ESC Heart Failure, EarlyView.
In this retrospective, observational study of a real‐life cohort of patients with heart failure with reduced ejection fraction, long‐term survival was improved in patients who achieved sustained reverse remodeling. Greater increases in ejection fraction (EF) and reductions in left ventricular end‐systolic diameter at the time of EF recovery, greater ...
Silas Ramos Furquim, Edimar Alcides Bocchi, Maria Tereza Sampaio de Sousa Lira, Mauro Rogerio de Barros Wanderley Jr, Daniel Catto de Marchi, Pamela Camara Maciel, Andre Zimerman, Felix Jose Alvarez Ramires, Luciano Nastari, Bruno Biselli, Paulo Roberto Chizzola, Robinson Tadeu Munhoz, Fábio Fernandes, Silvia Moreira Ayub‐Ferreira   +13 more
wiley   +1 more source

Gut Microbiome and Pulmonary Arterial Hypertension - A Novel and Evolving Paradigm. [PDF]

Physiol Res
Thenappan T, Weir EK.
europepmc   +1 more source

Ambrisentan Therapy for Pulmonary Arterial Hypertension

, 2005
Nazzareno Galiè, David B. Badesch, Ronald J. Oudiz, Gérald Simonneau, Michael D. McGoon, Anne Keogh, Adaani Frost, Diane Zwicke, Robert Naeije, Shelley Shapiro, Horst Olschewski, Lewis J. Rubin   +11 more
openalex   +1 more source

H2FPEF and HFA‐PEFF scores for heart failure risk stratification in hypertrophic cardiomyopathy patients

ESC Heart Failure, EarlyView.
Abstract Aims H2FPEF and HFA‐PEFF scores have demonstrated prognostic value in heart failure (HF) with preserved ejection fraction. This study aimed to explore the value of the H2FPEF and HFA‐PEFF scores for HF risk stratification in patients with hypertrophic cardiomyopathy (HCM).
Yi‐Peng Gao, Hong‐Yun Liu, Xiao‐Jun Bi, Jie Sun, Ying Zhu, Wei Zhou, Ya‐Ting Fan, Xue‐Qing Cheng, Pei‐Na Huang, Ya‐Ni Liu, You‐Bin Deng   +10 more
wiley   +1 more source